
Adaptimmune Therapeutics plc ADAP
Quartalsbericht 2025-Q2
hinzugefügt 13.08.2025
Adaptimmune Therapeutics plc P/S 2011-2026 | ADAP
P/S Jährlich Adaptimmune Therapeutics plc
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 34 | 46.3 | 444 | 1.18 K | 2.25 M | 45.8 K | 121 K | 125 K | 737 | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 2.25 M | 34 | 282 K |
P/S anderer Aktien in der Pharmaeinzelhändler
| Name | P/S | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Assembly Biosciences
ASMB
|
4.27 | $ 28.46 | 3.45 % | $ 319 M | ||
|
Ascendis Pharma A/S
ASND
|
947 | $ 221.88 | -0.87 % | $ 5 B | ||
|
MorphoSys AG
MOR
|
1.75 | - | 2.43 % | $ 254 M | ||
|
Axsome Therapeutics
AXSM
|
13.6 | $ 156.92 | -1.23 % | $ 7.81 B | ||
|
Pharming Group N.V.
PHAR
|
4.67 | $ 15.36 | -0.71 % | $ 7.59 B | ||
|
Autolus Therapeutics plc
AUTL
|
1.37 K | $ 1.37 | -4.2 % | $ 350 M | ||
|
Kamada Ltd.
KMDA
|
2.61 | $ 8.5 | -1.39 % | $ 260 M | ||
|
I-Mab
IMAB
|
94.1 | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
5.53 | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
1.96 K | - | 2.54 % | $ 160 B | ||
|
Benitec Biopharma
BNTC
|
54.5 | $ 10.98 | -4.52 % | $ 452 M | ||
|
Inventiva S.A.
IVA
|
128 | $ 5.78 | -4.3 % | $ 138 M | ||
|
Compugen Ltd.
CGEN
|
49.8 | $ 2.09 | -0.95 % | $ 195 M | ||
|
Midatech Pharma plc
MTP
|
137 | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.39 K | - | -1.52 % | $ 24.7 M | ||
|
Aeterna Zentaris
AEZS
|
7.87 | - | 5.93 % | $ 314 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
65.5 | - | - | $ 26.5 M | ||
|
Acorda Therapeutics
ACOR
|
0.142 | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
0.203 | - | 4.01 % | $ 150 M | ||
|
Foghorn Therapeutics
FHTX
|
11.5 | $ 5.0 | 2.25 % | $ 315 M | ||
|
Институт стволовых клеток человека
ISKJ
|
2.61 | - | - | - | ||
|
Adverum Biotechnologies
ADVM
|
76.4 | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
25.8 | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
144 | - | -9.65 % | $ 45.9 M | ||
|
AbCellera Biologics
ABCL
|
12.8 | $ 3.4 | -3.68 % | $ 1.02 B | ||
|
BioMarin Pharmaceutical
BMRN
|
3.63 | $ 54.13 | -1.64 % | $ 10.4 B | ||
|
Curis
CRIS
|
1.21 | $ 0.77 | 1.89 % | $ 4.86 M | ||
|
AgeX Therapeutics
AGE
|
0.099 | - | -10.17 % | $ 12.2 K | ||
|
Coherus BioSciences
CHRS
|
5.36 | $ 1.52 | -5.59 % | $ 178 M | ||
|
Aeglea BioTherapeutics
AGLE
|
489 | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
281 | - | - | $ 867 M | ||
|
Burford Capital Limited
BUR
|
6.35 | $ 7.7 | -5.87 % | $ 1.29 B | ||
|
Cellectis S.A.
CLLS
|
6.69 | $ 3.34 | -4.02 % | $ 116 M | ||
|
Arbutus Biopharma Corporation
ABUS
|
24.5 | $ 4.24 | -2.97 % | $ 704 M | ||
|
Albireo Pharma
ALBO
|
13.3 | - | -0.23 % | $ 916 M | ||
|
AIkido Pharma
AIKI
|
1.08 | - | 1.93 % | $ 17.4 M | ||
|
Cardiff Oncology
CRDF
|
196 | $ 1.8 | -1.1 % | $ 120 M | ||
|
Cabaletta Bio
CABA
|
50.3 M | $ 2.94 | -3.29 % | $ 3.43 M | ||
|
Iterum Therapeutics
ITRM
|
985 | $ 0.16 | -5.45 % | $ 3.15 M | ||
|
Brickell Biotech
BBI
|
1.42 | - | -5.38 % | $ 6.06 M |